Human Papilloma Virus Infection Type 16 Clinical Trial
Official title:
Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)
Cecolin is the first Chinese domestic human papillomavirus (HPV) vaccine. Cecolin is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Hecolin is the first prophylactic vaccine against hepatitis E virus (HEV). The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with Cecolin and Hecolin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02546752 -
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
|
Phase 0 | |
| Completed |
NCT02733068 -
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
|
Phase 3 | |
| Completed |
NCT02558803 -
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
|
N/A | |
| Completed |
NCT02551887 -
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
|
N/A | |
| Active, not recruiting |
NCT05669911 -
Development of a Self-collection Device for Cervical Cancer Screening
|
N/A | |
| Active, not recruiting |
NCT05279248 -
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
|
Phase 4 |